Investment Rating - The report maintains a "Buy" rating for Weigao, AK Medical, and AngelAlign, while holding a "Neutral" rating for Jinxin and Tigermed [2][3][13]. Core Insights - The report indicates a cautious optimism regarding the recovery of surgical volumes in 2025, with expectations of manageable impacts from recent regulatory changes and tariff adjustments [1][4]. - The focus is shifting towards internal operational management and shareholder returns, with companies emphasizing cash flow management and reducing capital expenditures [8][11]. Summary by Sections Surgical Volume and Regulatory Environment - Surgical volume is expected to trend positively in 2025, with many companies reporting improved sentiment at the start of the year [4]. - The impact of the Value-Based Pricing (VBP) is seen as manageable, with major players focusing on market share gains [4][7]. Company-Specific Developments - Weigao anticipates a revenue growth of 10-15% year-on-year in FY25, driven by new product ramp-ups [9]. - AK Medical's market share in Tier 1 hospitals has increased significantly, and the company expects continued growth in overseas markets [4][9]. - AngelAlign is focusing on overseas expansion, particularly in Europe, with a projected 50% year-on-year increase in overseas case volumes [9][19]. Financial Guidance and Earnings Revisions - The report revises sales estimates downwards for several companies, with average changes of -1.6% to -2.2% for 2025-2027 and earnings estimates down by -13.3% to -16.7% [1][14]. - Gushengtang expects revenue growth to exceed 25% year-on-year in FY25, while Jinxin did not provide specific revenue guidance due to uncertainties [8][19]. Target Price Changes - Target prices have been adjusted for several companies, with Hygeia's target price set at HK$27.60, AngelAlign at HK$76.20, and Gushengtang at HK$46.00 [13][17][18].

Market Overview - The market showed a strong upward trend, with the Shanghai Composite Index recovering above 3400 points, reaching a new high for the year at 3419.56, up 1.81% [2][3] - The Shenzhen Component Index and the ChiNext Index also experienced significant gains, with increases of 2.26% and 2.80% respectively [2][3] - Overall, nearly 4500 stocks rose, with close to 100 stocks hitting the daily limit up [3] Sector Performance - The top-performing sectors included Food & Beverage (5.41%), Non-Bank Financials (3.97%), and Retail (3.18%) [2] - Conversely, sectors such as Steel and Coal showed negative performance, with declines of -0.52% and -0.12% respectively [2] - Concept indices like Dairy, Three-Child Policy, and Community Group Buying performed well, while sectors like Smart Lamp Poles and Coal Concepts lagged [3] Monetary Policy Insights - The People's Bank of China emphasized the implementation of a moderately loose monetary policy, indicating potential for reserve requirement ratio (RRR) and interest rate cuts [4] - Financial regulatory authorities are encouraging banks to increase personal consumption loan offerings to boost consumer spending [4] Market Sentiment and Technical Analysis - The trading volume in the Shanghai and Shenzhen markets reached 1.79 trillion, indicating active market sentiment [5] - Technical indicators suggest a strong upward momentum, with the Shanghai Composite Index positioned above its 5-day moving average [5] - The report anticipates a systematic revaluation of Chinese assets, supported by ongoing macroeconomic adjustments and growth stabilization policies [5] Investment Focus - Recommended sectors for investment include Technology, Media, Telecommunications (TMT), Financials, and Consumer sectors [5]